Plasmin variants and uses thereof

Details Plasmin variants and uses thereof Plasmin variants and uses thereof

2006-01-24

2006-01-24

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S252300, C435S041000, C435S068100, C424S094640

Reexamination Certificate

active

06989262

ABSTRACT:
The invention concerns plasmin variants. Polynucleotides the disclosed plasmin variants are provided. Additionally, methods of using the plasmin polynucleotides and polynucleotides are provided herein.

REFERENCES:
patent: 5753486 (1998-05-01), Goeddel et al.
patent: 2002/0004586 (2002-01-01), Aguzzi et al.
patent: WO 94/03614 (1994-02-01), None
Whisstock et al Prediction of protein function from protein sequence and structure. ≃≃Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
Elkon et al Use of synthetic peptides for the detection and quantification of autoantibodies. Mol Biol Rep. Jun. 1992;16(3):207-12. Review.
SwissProt_42 Database Accession No. PLMN_Human Mar. 1, 1989 from Petersen et al Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem. Apr. 15, 1990;265(11):6104-6111. Alignment with SEQ ID No. 54.
Danis, R., et al.; “Anti-angiogenic therapy of proliferative diabetic retinopathy”; Exp.Opin.Pharmacather. (2001) 2(3):395-407; Ashley Publication Ltd. ISSN 1465-6566.
Castellino, Francis; “Plasminogen”; pp. 495-515; Molecular Basis of Thrombosis and Hemostasis edited by Katherine A. High & Harold R. Roberts; Marcel Dekker, Inc., New York, NY; (1995) ISBN 0-8247-9501-6.
Ellenrieder, V., et al.; “Invasion and metastasis in pancreatic cancer”; Annals of Oncology, 10, suppl. 4, 41-45, 1999; Kluwer Academic Publishers, Netherlands.
Moroz, L., et al.; “Mini-Plasminogen-like Fragments of Plasminogen in Synovial Fluid in Acute Inflammatory Arthritis”; Thrombosis Research 43: 417-424, 1986: 0049-3848/86; Pergamon Journals Ltd.
Carmeliet, P., et al.: “Impaired Arterial Neointime Formation in Mice with Disruption of the Plasminogen Gene”; J. Clin. Invest; vol. 99, No. 2, Jan. 1997, 200-208; The American Society for Clinical Investigation, Inc.; 0021-9738/97/01/200/09.
Swiercz, R., et al.; “Recombinant PAI-1 Inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice”; Oncology Reports 8:463-470, 2001.
Castellino, F., et al.; “The kringle domains of human plasminogen”; Ciba Found Symp 212:46-60 (1997).
Moroz, L., et al.; “Mini-Plasminogen: A Mechanism for Leukocyte Modulation of Plasminogen Activation by Urokinase”; Blood, vol. 58, No. 1 (Jul.) 1981 p. 97-104; Gruie & Stratton, Inc.;0006-4971/81/5801-0014.
Bewley, Thomas: “Optical Activity of Disulfide Bonds in Proteins. 1. Studies on Plasmin Modified Human Somatotropin”; Biochemistry vol. 16, No. 2, 1977, p. 209-215.
Kost, C., et al.; “Limited plasminproteolysis of vitronectin—Characerizationof the adhesion proteins as morpho-regulatory and angiostatin-binding factor”; Eur. J. Biochem. 238, 682-688 (1996); FEBS 1996.
Morii, T., et al.; “Prognostic Relevance of Urokinase Type Plasminogen Activator, Its Receptor and Inhibitors in Chondrosarcoma”; Anticancer Research 20: 3031-3036 (2000); 0250-705/2000.
Konno, H., et al.; “Urokinase Receptor and Vascular Endothelial Growth Factor are Synergistically Associated with Liver Metastasis of Colorectal Cancer”; Jpn. J.Cancer Res.; 92, 516-523, May 2001.
Romer, J., et al.; “Cancer Cell Expressionof Urokinase-Type Plasminogen Activator Receptor mRNA in Squamous Cell Carcinomas of the Skin”; The Journal of Investigative Dermatology; vol. 116, No. 3, Mar. 2001, pp. 353-358; The Society for Investigative Dermatology, Inc.; 0022-202X/01.
Itoh, Y., et al.; “Highly Increased Plasma Concentrations of the Nicked form of B2Glycoprotein in Patients with Leukemia and with Lupus Anticoagulant Measurement with a Monoclonal Antibody Specific for a Nicked Form of Domain V”; J.Biochem, vol. 128, No. 6, pp. 1017-1024 (2000).
Andreasen, et al.; “The plasminogen activation system in tumor growth, invasion, and metastasis”; CMLS Cellular and Molecular Life Sciences, 57 (2000) 25-40; 1420-682X/00/010025-16; Birkhauser Verlag, Basel.
Shi, G.Y., et al.; “Isolation and Characterization of Microplasminogen”; The Journal of Biological Chemistry, vol. 263, No. 32, Issue of Nov. 15, pp. 17071-17075, 1988; The American Society for Biochemistry and Molecular Biology, Inc.
Creemers, et al.; “Disruption of the Plasminogen Gene in Mice Abolished Wound Healing after Myocardial Infarction”; American Journal of Pathology, vol. 156, No. 6, Jun. 2000 p. 1865-1875: American Society for Investigative Pathology.
Petersen, T., et al.; “Characterization of the Gene for Human Plasminogen, a key Proenzyme in the Fibrinolytic System”; The Journal of Biological Chemistry, vol. 265, No. 11, Issue of Apr. 15, pp. 6104-6111, 1990; The American Society for Biochemistry and Molecular Biology, Inc.
He, C., et al.; “Analysis of expression of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells”; J. Cancer Res Clin Oncol (2001) 127:180-186; Springer-Verlag 2000.
Borgfeldt, C.; Dedifferentiation of Serous Ovarian Cancer from Cystic to Solid Tumors is Associated with Increased Expression of mRNA for Urokinase Plasminogen Activator (uPA), its Receptor (uPAR) and its Inhibitor (PAI-1); Int. J. Cancer; 92, 497-502 (2001); Wiley-Liss, Inc.; Publication of the International Union Against Cancer.
Tecimer, C., et al.; “Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer”; Gynecologic Oncology 80, 48-55 (2001); 0090-8258/01; Academic Press.
Zheng, Q., et al.; “Invasion and metastasis of hepatocellular carcinoma inrelation to urokinase-type plasminogen activator, its receptor and inhibitor”; J Cancer Res Clin Oncol (2000) 126:641-646; Springer-Verlag 2000.
Abe, J., et al.; “Larger and More Invasive Colorectal Carcinoma Contains Larger Amounts of Plasminogen Activator Inhibitor Type 1 and Its Relative Ratio over Urokinase Receptor Correlates Well with Tumor Size”; Cancer, Dec. 15, 1999; vol. 86, No. 12, pp. 2602-2611; 199 American Cancer Society.
Fisher, J., et al.; “The Expression of the Urokinase Plasminogen Activator System in Metastic Murine Osteosarcoma: An in Vivo Mouse Model”; Clinical Cancer Research; vol. 7, 1654-1660. Jun. 2001.
Romer, J., et al.; “Impaired wound healing in mice with a disrupted plasminogen gene”; Nature Medicine, vol. 2, No. 3, Mar. 1996, pp. 287-292.
Accession No: AAR34428; Foster, et al.; “Human tissue plasminogen activator single chain form fibrinolytic agent—comprises thrombin cleavable zymogen stimulating amido lytic activity, for lysing clots in heart attack and stroke victims and suppressing fibrin matrix”.
Accession No: AAR56472; Dawson, et al.; “New modified serine protease(s) resistant to inhibitors—having a mutation at a residue in close spatial proximity to a site of interaction between the protease and inhibitor”.
NCBI Data Base Accession No. CAA02277; Dawson, et al.; “Inhibitor resistant serine proteases”.
NCBI Data Base Accession No. P00747; Petersen, et al.; “Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system”.
NCBI Data Base Accession No. AL109933; Tracey, A.; “Human DNA sequence from clone RP1-81D8 on chromosome 6q25.3-26”.
AAGeneSeq database; Accession No. AAR34428; Foster et al.; “Human tissue plasminogen activator single chain form fibrinolytic agent comprises thrombin cleavable zymogen stimulating amido lytic activity, for lysing clots in heart attack and stroke victims and suppressing fibrin matrix”.
AAGeneSeq database; Accession No. AAR56472; Dawson et al.; “New modified serine protease(s) resistant to inhibitors having a mutation at a residue in close spatial proximity to a site of interaction between the protease and inhibitor”.

Affiliated with

Also associated with

Rating

Plasmin variants and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Plasmin variants and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmin variants and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3533658